Profile
Presently, Craig Paterson is Chief Medical Officer at Allakos, Inc. In the past he was Chief Medical Officer at Endo International Plc and Senior VP-Medical & Clinical Development at Salix Pharmaceuticals Ltd. He received a graduate degree from McMaster University and an MBA from the University of Tennessee.
Former positions of Craig Paterson
| Companies | Position | End |
|---|---|---|
| ALLAKOS INC. | Chief Tech/Sci/R&D Officer | 09/02/2024 |
UMass Chan Medical School
UMass Chan Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Vivelix Pharmaceuticalsc Corp. | Founder | - |
| ENDO INTERNATIONAL PLC | Chief Tech/Sci/R&D Officer | - |
| SALIX PHARMACEUTICALS, LTD. | Corporate Officer/Principal | - |
Training of Craig Paterson
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Salix Pharmaceuticals Ltd.
Salix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops prescription drugs | Health Technology |
Endo International Plc
Endo International Plc Pharmaceuticals: MajorHealth Technology Develops and manufactures immunology, urology, hepatology, generics & sterile injectables therapeutics products | Health Technology |
McMaster University
McMaster University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Tennessee
University of Tennessee Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UMass Chan Medical School
UMass Chan Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Allakos, Inc.
Allakos, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company that develops innovative therapeutics which target immunomodulatory receptors for the treatment of allergic, inflammatory and proliferative diseases | Health Technology |
Vivelix Pharmaceuticalsc Corp. |
- Stock Market
- Insiders
- Craig Paterson
















